Post date November 14, 2022 Experience Atour Lifestyle Holdings $52 million IPO We advised Atour on its IPO and Nasdaq listing
Post date November 14, 2022 Experience Snail $15 million IPO We advised Snail on its IPO and Nasdaq listing
Post date October 25, 2022 Experience Prime Medicine $175 million IPO The shares are listed on the Nasdaq Global Market
Post date September 22, 2022 Experience InnoCare Pharma RMB2.9 billion Shanghai IPO This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Post date September 21, 2022 Experience Nayax direct listing The shares are listed on the Nasdaq Global Select Market
Post date September 19, 2022 Experience Interra Acquisition HK$1 billion IPO We advised the SPAC on its IPO and HKEX listing
Post date September 1, 2022 Experience Biocytogen HK$549 million IPO We advised Biocytogen on its IPO and HKEX listing
Post date July 12, 2022 Experience Tuya global offering and dual primary listing on the Hong Kong Stock Exchange We advised Tuya Inc. on its HK$141 million global offering and dual primary listing on the HKEX
Post date May 18, 2022 Experience Financials Acquisition £150 million IPO The shares are listed on the London Stock Exchange
Post date May 17, 2022 Experience Beike’s dual primary listing on the Hong Kong Stock Exchange This is the first dual primary listing by way of introduction with WVR structure on the HKEX